Akin Atmaca

6.2k total citations · 2 hit papers
61 papers, 3.3k citations indexed

About

Akin Atmaca is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Akin Atmaca has authored 61 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Akin Atmaca's work include Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (13 papers) and Lung Cancer Treatments and Mutations (12 papers). Akin Atmaca is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (13 papers) and Lung Cancer Treatments and Mutations (12 papers). Akin Atmaca collaborates with scholars based in Germany, United States and Switzerland. Akin Atmaca's co-authors include Elke Jäger, Alexander Knuth, Salah‐Eddin Al‐Batran, Claudia Pauligk, Matthew D. Hellmann, Scott Antonia, Paolo A. Ascierto, Margaret K. Callahan, Emiliano Calvo and G. Seipelt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Cell.

In The Last Decade

Akin Atmaca

54 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

2018 670 citations Matthew D. Hellmann, Margaret K. Callahan et al. Cancer Cell profile →
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

2008 568 citations Salah‐Eddin Al‐Batran, Claudia Pauligk et al. profile →

Peers

Countries citing papers authored by Akin Atmaca

Since Specialization

Citations

This map shows the geographic impact of Akin Atmaca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akin Atmaca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akin Atmaca more than expected).

Fields of papers citing papers by Akin Atmaca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akin Atmaca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akin Atmaca. The network helps show where Akin Atmaca may publish in the future.

Co-authorship network of co-authors of Akin Atmaca

This figure shows the co-authorship network connecting the top 25 collaborators of Akin Atmaca. A scholar is included among the top collaborators of Akin Atmaca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akin Atmaca. Akin Atmaca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1857P Eftilagimod alpha (soluble LAG-3 protein) combined with first-line chemo-immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC): Updates from INSIGHT-003 (IKF614) 2025 ·Annals of Oncology ·Akin Atmaca, (unknown), (unknown), (unknown), Alex Stein, Daniel Pink, Christian Becker, Werner J. Blau, (unknown), (unknown), (unknown), (unknown), (unknown), E. Jaeger, David W.M. Muller, (unknown), (unknown), Sabine Gehrke-Beck, S-E. Al-Batran, Thorsten Oliver Goetze	0
2	Multiple infusions of TILs expanded with IL-2/IL-15/IL-21 lead to an improved PK/PD profile and long-term clinical responses in patients with cold tumors 2025 ·Cytotherapy ·Lucas C. M. Arruda, Julia Karbach, (unknown), H. Altmannsberger, (unknown), (unknown), (unknown), Akin Atmaca, Elke Jäger	0
3	Tumor-infiltrating lymphocytes-derived CD8 ⁺ clonotypes infiltrate the tumor tissue and mediate tumor regression in glioblastoma 2025 ·OncoImmunology ·Lucas C. M. Arruda, Julia Karbach, (unknown), Hans‐Michael Altmannsberger, (unknown), (unknown), (unknown), Akin Atmaca, Elke Jäger	0
4	1042P INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas 2023 ·Annals of Oncology ·Akin Atmaca, David W.M. Muller, (unknown), (unknown), (unknown), (unknown), Elke Jäger, S-E. Al-Batran, Thorsten Oliver Goetze	2
5	Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer 2023 ·Journal for ImmunoTherapy of Cancer ·Julia Karbach, (unknown), Kathrin Brand, Claudia Wahle, (unknown), (unknown), (unknown), (unknown), Akin Atmaca, Elke Jäger	9
6	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer breakdown → 2018 ·Cancer Cell ·Matthew D. Hellmann, Margaret K. Callahan, Mark M. Awad, Emiliano Calvo, Paolo A. Ascierto, Akin Atmaca, Naiyer A. Rizvi, Fred R. Hirsch, Giovanni Selvaggi, Joseph D. Szustakowski, Ariella Sasson, Ryan Golhar, Patrik Vitazka, Chang Han, William J. Geese, Scott Antonia	670
7	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 2018 ·Journal of Thoracic Oncology ·Neal Ready, Anna F. Farago, Filippo de Braud, Akin Atmaca, Matthew D. Hellmann, Jeffrey Schneider, David R. Spigel, Víctor Moreno, Ian Chau, Christine L. Hann, Joseph P. Eder, Nicola Steele, Anne Pieters, Justin Fairchild, Scott Antonia	233
8	SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer 2015 ·BMC Cancer ·Akin Atmaca, (unknown), Dominique Werner, K. Steinmetz, (unknown), Wolfgang M. Brueckl, Elke Jäger, Salah‐Eddin Al‐Batran	19
9	Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates 2014 ·Cancer Immunology Research ·Julia Karbach, Sacha Gnjatic, (unknown), Akin Atmaca, Eckhart Weidmann, (unknown), Claudia Wahle, Helga Bernhard, Alexander Knuth, Elke Jäger	12
10	Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer 2013 ·International Journal of Cancer ·Wolfgang M. Brueckl, Salah‐Eddin Al‐Batran, Joachim H. Ficker, (unknown), Akin Atmaca, Arndt Hartmann, Ralf J. Rieker, Ralph M. Wirtz	21
11	A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer 2013 ·British Journal of Cancer ·Akin Atmaca, S-E. Al-Batran, Dominique Werner, Claudia Pauligk, (unknown), (unknown), H. Bernhard, (unknown), (unknown), (unknown), K Caca, Nicole Prasnikar, Frank Kullmann, Hans‐Günter Derigs, Michael Koenigsmann, (unknown), T. Neuhaus, Elke Jäger	27
12	The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer 2012 ·BMC Cancer ·Akin Atmaca, Dominique Werner, Claudia Pauligk, K. Steinmetz, (unknown), Hans‐Michael Altmannsberger, Elke Jäger, Salah‐Eddin Al‐Batran	43
13	Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas 2011 ·Annals of Oncology ·Eckhart Weidmann, Antje Neumann, F. Fauth, Akin Atmaca, S. Al-Batran, Claudia Pauligk, Elke Jäger	65
14	Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer 2011 ·Oncology ·Akin Atmaca, Claudia Pauligk, K. Steinmetz, Hans‐Michael Altmannsberger, Elke Jäger, Salah‐Eddin Al‐Batran	13
15	Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients 2010 ·Clinical Cancer Research ·Julia Karbach, Antje Neumann, Akin Atmaca, Claudia Wahle, Kathrin Brand, Lotta von Boehmer, Alexander Knuth, Armin Bender, Gerd Ritter, Lloyd J. Old, Elke Jäger	63
16	Langzeitremission bei malignem Melanom Stadium IV nach antigenspezifischer Immuntherapie 2010 ·Medizinische Klinik ·Antje Neumann, Julia Karbach, Akin Atmaca, Elke Jäger	0
17	Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m<sup>2</sup> Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer 2006 ·Oncology ·Salah‐Eddin Al‐Batran, H.G. Meerpohl, Gϋnter von Minckwitz, Akin Atmaca, Ulrich R. Kleeberg, Nadia Harbeck, (unknown), (unknown), Jalid Sehouli, Alexander Knuth, Elke Jäger	44
18	Synergistic Effects of Valproic Acid and Mitomycin C in Adenocarcinoma Cell Lines and Fresh Tumor Cells of Patients with Colon Cancer 2006 ·Journal of Chemotherapy ·I. Friedmann, Akin Atmaca, (unknown), Elke Jäger, (unknown)	21
19	Dose Escalation Study for Defining the Maximum Tolerated Dose of Continuous Oral Trofosfamide in Pretreated Patients with Metastatic Lung Cancer 2004 ·Oncology Research and Treatment ·Salah-Eddin Al-Batran, Akin Atmaca, (unknown), D.H.J. Jager, (unknown), Antje Neumann, (unknown), A. Knuth, Eliézer Jäger	3
20	Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51 2002 ·PubMed ·Elke Jäger, Julia Karbach, Sacha Gnjatic, Dirk Jäger, Markus Maeurer, Akin Atmaca, Michael Arand, Jonathan Skipper, Elisabeth Stockert, Yao‐Tseng Chen, Lloyd J. Old, Alexander Knuth	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact